miR-181c associates with tumor relapse of high grade osteosarcoma

Oncotarget

Volumn 6, Issue 16, 2015, Pages 13947-13961

  Federica, Mori ^a   Andrea, Sacconi ^a   Valeria, Canu ^a   Federica, Ganci ^a   Mariangela, Novello ^b   Vincenzo, Anelli ^a   Renato, Covello ^a   Virginia, Ferraresi ^a   Paola, Muti ^c   Roberto, Biagini ^a   Giovanni, Blandino ^a,c   Sabrina, Strano ^a,c  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Giant cell tumor; miRNA profiling; Osteosarcoma; Relapse

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; MICRORNA; MICRORNA 155; MICRORNA 181A; MICRORNA 181C; MICRORNA 193A; MICRORNA 198; MICRORNA 378; MICRORNA 483 5P; MICRORNA 630; UNCLASSIFIED DRUG; MICRORNA 193A 5P; MIRN181 MICRORNA, HUMAN;

ADULT; ARTICLE; BONE RADIOGRAPHY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; DEATH; DISEASE DURATION; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ASSOCIATION; GIANT CELL TUMOR; HIP PAIN; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; MOLECULAR EVOLUTION; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; STROMA CELL; YOUNG ADULT; ADOLESCENT; BONE DEVELOPMENT; CANCER GRADING; CELL DEATH; CELL VIABILITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN CELL; IN VITRO STUDY; MALE; MALIGNANT TRANSFORMATION; MIDDLE AGED; OSTEOCLASTOMA; OSTEOLYSIS; OSTEOSARCOMA CELL LINE; PREDICTION; SCHOOL CHILD; TREATMENT OUTCOME; BONE TUMOR; CELL SURVIVAL; GENETICS; PATHOLOGY; TUMOR CELL LINE; TUMOR RECURRENCE;

ADULT; BONE NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; MICRORNAS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; YOUNG ADULT;

EID: 84931035414     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Ottaviani G and Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009; 152:3-13.
2. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8(12):915-928.
3. Savage SA and Mirabello L. Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma. 2011; 2011:548151.
4. Kresse SH, Rydbeck H, Skarn M, Namlos HM, Barragan-Polania AH, Cleton-Jansen AM, Serra M, Liestol K, Hogendoorn PC, Hovig E, Myklebost O and Meza-Zepeda LA. Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma. PLoS One. 2012; 7(11):e48262.
5. Fechner RE MS. Tumors of the bones and joints. Atlas of Tumor Pathology. 1993; fascicle 8:161-163.
6. Cowan RW and Singh G. Giant cell tumor of bone: a basic science perspective. Bone. 2013; 52(1):238-246.
7. Ghert M, Simunovic N, Cowan RW, Colterjohn N and Singh G. Properties of the stromal cell in giant cell tumor of bone. Clinical orthopaedics and related research. 2007; 459:8-13.
8. Hasegawa T, Hirose T, Seki K, Sano T and Hizawa K. Transforming growth factor alpha and CD68 immunoreactivity in giant cell tumours of bone: a study on the nature of stromal and giant cells, and their interrelations. J Pathol. 1993; 170(3):305-310.
9. Hoang BH, Kubo T, Healey JH, Yang R, Nathan SS, Kolb EA, Mazza B, Meyers PA and Gorlick R. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer research. 2004; 64(8):2734-2739.
10. Murata A, Fujita T, Kawahara N, Tsuchiya H and Tomita K. Osteoblast lineage properties in giant cell tumors of bone. J Orthop Sci. 2005; 10(6):581-588.
11. Nishimura M, Yuasa K, Mori K, Miyamoto N, Ito M, Tsurudome M, Nishio M, Kawano M, Komada H, Uchida A and Ito Y. Cytological properties of stromal cells derived from giant cell tumor of bone (GCTSC) which can induce osteoclast formation of human blood monocytes without cell to cell contact. J Orthop Res. 2005; 23(5):979-987.
12. Robinson D, Segal M and Nevo Z. Giant cell tumor of bone. The role of fibroblast growth factor 3 positive mesenchymal stem cells in its pathogenesis. Pathobiology. 2002; 70(6):333-342.
13. Salerno M, Avnet S, Alberghini M, Giunti A and Baldini N. Histogenetic characterization of giant cell tumor of bone. Clinical orthopaedics and related research. 2008; 466(9):2081-2091.
14. Wulling M, Delling G and Kaiser E. The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum Pathol. 2003; 34(10):983-993.
15. Lucas D. Giant Cell Tumor of Bone. Surgical Pathology. 2012; 5:183-200.
16. Campanacci M, Baldini N, Boriani S and Sudanese A. Giant-cell tumor of bone. The Journal of bone and joint surgery American volume. 1987; 69(1):106-114.
17. Bertoni F, Bacchini P and Staals EL. Malignancy in giant cell tumor. Skeletal radiology. 2003; 32(3):143-146.
18. Brien EW, Mirra JM, Kessler S, Suen M, Ho JK and Yang WT. Benign giant cell tumor of bone with osteosarcomatous transformation ("dedifferentiated" primary malignant GCT): report of two cases. Skeletal radiology. 1997; 26(4):246-255.
19. Grote HJ, Braun M, Kalinski T, Pomjanski N, Back W, Bleyl U, Bocking A and Roessner A. Spontaneous malignant transformation of conventional giant cell tumor. Skeletal radiology. 2004; 33(3):169-175.
20. Hashimoto K, Hatori M, Hosaka M, Watanabe M, Hasegawa T and Kokubun S. Osteosarcoma arising from giant cell tumor of bone ten years after primary surgery: a case report and review of the literature. Tohoku J Exp Med. 2006; 208(2):157-162.
21. Marui T, Yamamoto T, Yoshihara H, Kurosaka M, Mizuno K and Akamatsu T. De novo malignant transformation of giant cell tumor of bone. Skeletal radiology. 2001; 30(2):104-108.
22. Mori Y, Tsuchiya H, Karita M, Nonomura A, Nojima T and Tomita K. Malignant transformation of a giant cell tumor 25 years after initial treatment. Clinical orthopaedics and related research. 2000; (381):185-191.
23. Sakkers RJ, van der Heul RO, Kroon HM, Taminiau AH and Hogendoorn PC. Late malignant transformation of a benign giant-cell tumor of bone. A case report. The Journal of bone and joint surgery American volume. 1997; 79(2):259-262.
24. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-297.
25. Cheng AM, Byrom MW, Shelton J and Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005; 33(4):1290-1297.
26. Li Z, Hassan MQ, Jafferji M, Aqeilan RI, Garzon R, Croce CM, van Wijnen AJ, Stein JL, Stein GS and Lian JB. Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. The Journal of biological chemistry. 2009; 284(23):15676-15684.
27. Sugatani T and Hruska KA. MicroRNA-223 is a key factor in osteoclast differentiation. J Cell Biochem. 2007; 101(4):996-999.
28. Vandenboom Ii TG, Li Y, Philip PA and Sarkar FH. MicroRNA and Cancer: Tiny Molecules with Major Implications. Curr Genomics. 2008; 9(2):97-109.
29. McGrath PJ. Giant-cell tumour of bone: an analysis of fiftytwo cases. J Bone Joint Surg Br. 1972; 54(2):216-229.
30. Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, Volinia S, Stein GS, Croce CM, Lian JB and Aqeilan RI. miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer research. 2012; 72(7):1865-1877.
31. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-2261.
32. Mosakhani N, Mustjoki S and Knuutila S. Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia. Molecular cytogenetics. 2013; 6(1):27.
33. Schonrock N, Humphreys DT, Preiss T and Gotz J. Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-beta. Journal of molecular neuroscience: MN. 2012; 46(2):324-335.
34. Ruan J, Lou S, Dai Q, Mao D, Ji J and Sun X. Tumor suppressor miR-181c attenuates proliferation, invasion, and self-renewal abilities in glioblastoma. Neuroreport. 2015; 26(2):66-73.
35. Li Y, Wang H, Li J and Yue W. MiR-181c modulates the proliferation, migration, and invasion of neuroblastoma cells by targeting Smad7. Acta biochimica et biophysica Sinica. 2014; 46(1):48-55.
36. Gougelet A, Pissaloux D, Besse A, Perez J, Duc A, Dutour A, Blay JY and Alberti L. Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. International journal of cancer Journal international du cancer. 2011; 129(3):680-690.
37. Zhang GJ, Zhou H, Xiao HX, Li Y and Zhou T. MiR-378 is an independent prognostic factor and inhibits cell growth and invasion in colorectal cancer. BMC cancer. 2014; 14(1):109.
38. Bisso A, Faleschini M, Zampa F, Capaci V, De Santa J, Santarpia L, Piazza S, Cappelletti V, Daidone M, Agami R and Del Sal G. Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell cycle. 2013; 12(11):1679-1687.
39. Mori F, Strano S and Blandino G. MicroRNA-181a/b: novel biomarkers to stratify breast cancer patients for PARPi treatment. Cell cycle. 2013; 12(12):1823-1824.
40. Jianwei Z, Fan L, Xiancheng L, Enzhong B, Shuai L and Can L. MicroRNA 181a improves proliferation and invasion, suppresses apoptosis of osteosarcoma cell. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34(6):3331-3337.
41. Shi L, Cheng Z, Zhang J, Li R, Zhao P, Fu Z and You Y. hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res. 2008; 1236:185-193.
42. Franchi A, Arganini L, Baroni G, Calzolari A, Capanna R, Campanacci D, Caldora P, Masi L, Brandi ML and Zampi G. Expression of transforming growth factor beta isoforms in osteosarcoma variants: association of TGF beta 1 with high-grade osteosarcomas. J Pathol. 1998; 185(3):284-289.
43. Glass DA, 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA and Karsenty G. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005; 8(5):751-764.
44. Linkhart TA, Mohan S and Baylink DJ. Growth factors for bone growth and repair: IGF, TGF beta and BMP. Bone. 1996; 19(1 Suppl):1S-12S.
45. Yang T, Grafe I, Bae Y, Chen S, Chen Y, Bertin TK, Jiang MM, Ambrose CG and Lee B. E-selectin ligand 1 regulates bone remodeling by limiting bioactive TGF-beta in the bone microenvironment. Proc Natl Acad Sci U S A. 2013; 110(18):7336-7341.
46. Posthumadeboer J, Piersma SR, Pham TV, van Egmond PW, Knol JC, Cleton-Jansen AM, van Geer MA, van Beusechem VW, Kaspers GJ, van Royen BJ, Jimenez CR and Helder MN. Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery. British journal of cancer. 2013; 109(8):2142-2154.
47. Zhao S, Kurenbekova L, Gao Y, Roos A, Creighton CJ, Rao P, Hicks J, Man TK, Lau C, Brown AM, Jones SN, Lazar AJ, Ingram D, Lev D, Donehower LA and Yustein JT. NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma. Oncogene. www.impactjournals.com/oncotarget 13961 Oncotarget 2015.
48. Zhang H, Wu H, Zheng J, Yu P, Xu L, Jiang P, Gao J, Wang H and Zhang Y. Transforming growth factor beta1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma. Stem cells. 2013; 31(3):433-446.
49. Sulahian R, Casey F, Shen J, Qian ZR, Shin H, Ogino S, Weir BA, Vazquez F, Liu XS, Hahn WC, Bass AJ, Chan V and Shivdasani RA. An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer. Oncogene. 2014; 33(49):5637-5648.
50. Park H, Drevelle O, Daviau A, Senta H, Bergeron E and Faucheux N. Preventing MEK1 activation influences the responses of human osteosarcoma cells to bone morphogenetic proteins 2 and 9. Anti-cancer drugs. 2013; 24(3):278-290.
51. Tanaka M, Setoguchi T, Hirotsu M, Gao H, Sasaki H, Matsunoshita Y and Komiya S. Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. British journal of cancer. 2009; 100(12):1957-1965.
52. Duan X, Liang YY, Feng XH and Lin X. Protein serine/threonine phosphatase PPM1A dephosphorylates Smad1 in the bone morphogenetic protein signaling pathway. The Journal of biological chemistry. 2006; 281(48):36526-36532.
53. Chau JF, Jia D, Wang Z, Liu Z, Hu Y, Zhang X, Jia H, Lai KP, Leong WF, Au BJ, Mishina Y, Chen YG, Biondi C, Robertson E, Xie D, Liu H, et al. A crucial role for bone morphogenetic protein-Smad1 signalling in the DNA damage response. Nature communications. 2012; 3:836.